Apr 25, 09:07
AnnouncementsRanbaxy to consider audited financial results
52 Week HighRanbaxy Labs has hit a 52wk high of Rs 505.00 on BSE
73% of moneycontrol users recommend buying Ranbaxy Labs.
What's your call on Ranbaxy Labs today?
Read 3 investor views
|Company Name||Last Price||%
|Dr Reddys Labs||2618.00||2.05||2939.80||1999.40||44,534.50|
|Mar' 14||Dec' 13||Sep' 13||Jun' 13|
|Scheme||No. of Shares|
|Kotak Equity Arbitrage Fund (G)||637,622|
|Reliance Arbitrage Advantage Fund (G)||345,212|
|Kotak Equity Arbitrage Fund - Direct Plan (G)||217,841|
|Reliance Arbitrage Advantage Fund - Direct Plan (G)||107,057|
Ranbaxy Labs is in the Pharmaceuticals sector. The current market capitalisation stands at Rs 20,113.82 crore.The company has reported a consolidated sales of Rs 2,858.96 crore and a Net Loss of Rs 158.49 crore for the quarter ended Dec 2013.
The company management includes Tsutomu Une - Chairman, Arun Sawhney - Managing Director & CEO, Akihiro Watanabe - Director, Anthony H Wild - Director, Kazunori Hirokawa - Additional Director, Rajesh V Shah - Director, Takashi Shoda - Director, Percy K Shroff - Director.
It is listed on the BSE with a BSE Code of 500359 and the NSE with an NSE Code of RANBAXY.
Its Registered office is at A-41, Industrial Area, Phase-VIII-A,,Sahibzada Ajit Singh Nagar Mohali,Punjab - 160071.
Their Registrars are Alankit Assignment Ltd.